Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elagolix Phase 4 Study for HMB in Uterine Fibroids
NCT03886220Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in Uterine Fibroids (UF) comparing Elagolix 150 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Were Responders With Menstrual Blood Loss (MBL) Volume < 80 mL at Final Month and >= 50% Reduction in MBL Volume From Baseline to the Final Month at Month 6. Started Apr 2019; status: completed.
02
Drugs
elagolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03886220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886220.